NIRVF (Nirvana Life Sciences) Ending Cash Position: $0.00 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Nirvana Life Sciences Ending Cash Position?

Nirvana Life Sciences NIRVF Ending Cash Position is $0.00 Mil as of Jan. 2026. The stock has 3 warning signs investors should review.

Nirvana Life Sciences's Ending Cash Position for the quarter that ended in Jan. 2026 was $0.00 Mil.

Nirvana Life Sciences's quarterly Ending Cash Position stayed the same from Jul. 2025 ($0.00 Mil) to Oct. 2025 ($0.00 Mil) and stayed the same from Oct. 2025 ($0.00 Mil) to Jan. 2026 ($0.00 Mil).

Nirvana Life Sciences's annual Ending Cash Position declined from Apr. 2023 ($0.01 Mil) to Apr. 2024 ($0.00 Mil) but then increased from Apr. 2024 ($0.00 Mil) to Apr. 2025 ($0.00 Mil).

Nirvana Life Sciences Ending Cash Position Related Terms

Nirvana Life Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Nirvana Life Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nirvana Life Sciences Ending Cash Position Chart

Nirvana Life Sciences Annual Data
Trend Oct18 Oct19 Oct20 Oct21 Apr22 Apr23 Apr24 Apr25
Ending Cash Position
Get a 7-Day Free Trial 0.38 0.03 0.01 0.00 0.00

Nirvana Life Sciences Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Nirvana Life Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nirvana Life Sciences's Ending Cash Position for the fiscal year that ended in Apr. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.001+0.001
=0.00

Nirvana Life Sciences's Ending Cash Position for the quarter that ended in Jan. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.484+-1.483
=0.00

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $0.00 Mil mean?
Nirvana Life Sciences (NIRVF) has a Ending Cash Position of $0.00 Mil as of Jan. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nirvana Life Sciences and its competitors.
Is Nirvana Life Sciences' Ending Cash Position too high?
Nirvana Life Sciences' current Ending Cash Position is $0.00 Mil.
How does Nirvana Life Sciences' Ending Cash Position compare to VRTX and REGN?
Nirvana Life Sciences' Ending Cash Position of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nirvana Life Sciences and its competitors. Nirvana Life Sciences's current Ending Cash Position is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nirvana Life Sciences stock overvalued right now?
Nirvana Life Sciences (NIRVF) has a current Ending Cash Position of $0.00 Mil. The current Ending Cash Position is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Nirvana Life Sciences (NIRVF), the current Ending Cash Position is $0.00 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nirvana Life Sciences Business Description

Other Exchanges NIRV.X:Canada
Address 650 West Georgia Street, Suite 2110, Vancouver, BC, CAN, V6B 4N8
Nirvana Life Sciences Inc is a Canada-based company, which is engaged in the scientific research and development of therapeutic products derived from psychedelics. The Company is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The Company operates in a single reportable segment: research and development of therapeutic products derived from psychedelics. The company is working on novel formulations of psilocybin and other naturally-sourced psychedelics to treat pain, opioid dependency, and other health problems.